AngioDynamics (ANGO) Granted FDA Approval to Begin NanoKnife DIRECT Clinical Study for Treatment of Stage III Pancreatic Cancer
Tweet Send to a Friend
AngioDynamics, Inc. (NASDAQ: ANGO) today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
